Rigel Pharmaceuticals, Inc. (RIGL)
NASDAQ: RIGL · Real-Time Price · USD
17.24
-0.42 (-2.35%)
At close: Apr 4, 2025, 4:00 PM
17.01
-0.23 (-1.31%)
After-hours: Apr 4, 2025, 7:58 PM EDT
Rigel Pharmaceuticals Revenue
In the year 2024, Rigel Pharmaceuticals had annual revenue of $179.28M with 54.71% growth. Rigel Pharmaceuticals had revenue of $57.60M in the quarter ending December 31, 2024, with 60.92% growth.
Revenue (ttm)
$179.28M
Revenue Growth
+54.71%
P/S Ratio
1.69
Revenue / Employee
$1,093,159
Employees
164
Market Cap
307.96M
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 179.28M | 63.40M | 54.71% |
Dec 31, 2023 | 115.88M | 140.00K | 0.12% |
Dec 31, 2022 | 115.74M | -22.99M | -16.57% |
Dec 31, 2021 | 138.74M | 30.12M | 27.72% |
Dec 31, 2020 | 108.62M | 49.33M | 83.21% |
Dec 31, 2019 | Pro | Pro | Pro |
Dec 31, 2018 | Pro | Pro | Pro |
Dec 31, 2017 | Pro | Pro | Pro |
Dec 31, 2016 | Pro | Pro | Pro |
Dec 31, 2015 | Pro | Pro | Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 400.28B |
Johnson & Johnson | 88.82B |
Merck & Co. | 64.17B |
AbbVie | 56.33B |
AstraZeneca | 54.07B |
Novartis AG | 51.72B |
Eli Lilly and Company | 45.04B |
Thermo Fisher Scientific | 42.88B |
RIGL News
- 1 day ago - Rigel Pharmaceuticals: 3-Drug Company Reaches Profitability - Seeking Alpha
- 1 day ago - Rigel Pharmaceuticals, Inc. Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4) - PRNewsWire
- 9 days ago - Rigel Announces Settlement Agreement Resolving TAVALISSE® (fostamatinib disodium hexahydrate) Patent Litigation - PRNewsWire
- 26 days ago - Rigel Appoints Mark W. Frohlich, M.D. - PRNewsWire
- 4 weeks ago - Rigel Pharmaceuticals, Inc. (RIGL) Q4 2024 Earnings Call Transcript - Seeking Alpha
- 4 weeks ago - Rigel Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update - PRNewsWire
- 5 weeks ago - Rigel Announces Conference Call and Webcast to Report Fourth Quarter and Full Year 2024 Financial Results and Business Update - PRNewsWire
- 2 months ago - Rigel's Fostamatinib Being Studied by National Institute of Health in Patients with Sickle Cell Disease - PRNewsWire